SLGL News and Press, Sol-Gel Technologies Ltd. From 11/28/23

Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (Nasdaq: S...

2023-11-09 13:10:38 ET More on Sol-Gel Technologies Seeking Alpha’s Quant Rating on Sol-Gel Technologies Historical earnings data for Sol-Gel Technologies Financial information for Sol-Gel Technologies For further details see: Sol-Gel Technologies ...

Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Gorlin Syndrome KOL event to be held on December 6, 2023 Sol-Gel maintains cash runway into the second half of 2025 NESS ZIONA, Israel, Nov. 09, 202...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Sol-Gel Technologies Ltd. (SLGL) is expected to report $-0.23 for Q3 2023

2023-10-06 13:29:08 ET Gainers: Falcon's Beyond Global  (FBYD) +145% . American Oncology Network  ( AONC ) +53% . Akso Health Group  ( AHG ) +23% . Vigil Neuroscience  ( VIGL ) +20% . NuScale Power Corporation ( SMR )...

NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, EPSOLAY and...

2023-08-10 12:22:30 ET Sol-Gel Technologies press release ( NASDAQ: SLGL ): Q2 GAAP EPS of -$0.24 beats by $0.02 . As of June 30, 2023, Sol-Gel had $29.1 million in cash, cash equivalents and deposits, and $17.9 million in marketable securities for a total balance of $...

Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently announced agreement with Searchlight Pharma will provide up to $11 million in upfront payments and regulatory and sales milestones for...

2023-06-06 12:42:07 ET Israel's Sol-Gel ( NASDAQ: SLGL ) has signed an exclusive licensing deal with Searchlight Pharma for the Canadian commercialization rights to its dermatology products Twyneo and Eposolay. Sol-Gel said it will receive up to $11M in upfront and milestone...